Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
A user on finasteride for hair loss is considering topical dutasteride to further reduce scalp DHT and is using various other topicals as substitutes for minoxidil due to concerns about the safety of their cats and potential heart side effects from oral minoxidil. They are exploring whether a once-weekly application of topical dutasteride would be effective.
User shares new hair growth stack including oral minox, daily rolling with minox application, niacin, and Dutasteride. Excited about progress and plans to update in two months.
Hair cloning updates, with potential costs ranging from $200,000 to $350,000. Clinical trials may start in 2020, and some hope for cheaper options in Turkey or China.
Methylsulfonylmethane (MSM) is not a treatment for male pattern baldness but can accelerate hair growth and thicken miniaturized hairs, with the side effect of increased hair growth all over the body. The user asks others to share their experiences with MSM.
The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.
The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.
The conversation discusses sourcing topical dutasteride for hair loss treatment, with mentions of Dr. Mwamba's products and Farmacia Prati as potential suppliers. Additional treatments like topical tocotrienols and botox are suggested as extensions to the regimen.
CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.
The conversation is about using topical cetirizine for hair loss treatment. The user mixes Aller-TEC tablets with a hair tonic but faces issues with the solution's consistency.
AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.
The post discusses using ImageJ software to objectively track hair regrowth progress. The user is treating Androgen alopecia with dutasteride and minoxidil.
The conversation is about a user considering a hair transplant with BlueMagic Group and seeking real experiences and advice. Users suggest verifying who performs the surgery, looking for long-term results, and ensuring thorough communication before proceeding.
A 20 year old male discussing his hair loss regimen, which includes using topical dutasteride, rogaine, RU58841, minoxidil and Avodart pills as well as scalp massage, stabbing head with steak knife, counting shed hairs under a hair net and sending them to a lab for analysis. Suggestions from other users include scalping method and switching to saw palmetto and zinc supplements.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.
A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.
The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.
Hair looks thinner in sunlight, and users discuss using hair fibers, minoxidil, finasteride, and considering dutasteride for hair loss. Hair fibers like Toppik help conceal thinning, and some users suggest additional treatments like derma stamping and micro-needling.
The conversation is about a person experiencing treatment-resistant androgenic alopecia despite using high doses of dutasteride and minoxidil, along with other treatments like microneedling and purilutamide. Suggestions include considering a hair transplant, checking medication authenticity, and exploring other treatments like RU58841 or topical estradiol.
KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.
A user underwent a second hair transplant for increased density and to address hair loss in the crown area, with 3,800 grafts at a cost of 2,200 euros at Estepalace, including additional services. Some commenters discussed the appearance of the hairline and the importance of using DHT blockers like finasteride or dutasteride post-transplant.
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
The conversation humorously speculates that bald Grey Aliens might be future humans who haven't solved baldness, despite advanced technology. Treatments like microneedling, minoxidil, and finasteride are mentioned as potential solutions.
The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.
The conversation discusses the anticipation of Chinese manufacturers producing Clascoterone 5% before its full approval in 2027. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
The conversation discusses past and current hair loss treatments, with the user reflecting on expensive peptide treatments like topical Dutasteride, Latanoprost, and others, which were ultimately deemed less effective than oral Dutasteride and Minoxidil. The user now prefers the latter due to their cost-effectiveness and efficacy.